Teacher Retirement System of Texas Increases Position in Recursion Pharmaceuticals, Inc. $RXRX

Teacher Retirement System of Texas boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 18.6% during the second quarter, Holdings Channel reports. The fund owned 79,567 shares of the company’s stock after acquiring an additional 12,452 shares during the period. Teacher Retirement System of Texas’ holdings in Recursion Pharmaceuticals were worth $403,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Recursion Pharmaceuticals by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company’s stock worth $4,566,000 after buying an additional 12,588 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Recursion Pharmaceuticals by 753.8% in the first quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock worth $706,000 after buying an additional 117,851 shares in the last quarter. Cerity Partners LLC purchased a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $332,000. Finally, ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company’s stock worth $184,174,000 after acquiring an additional 2,469,104 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Trading Down 2.4%

Shares of RXRX opened at $4.51 on Tuesday. The stock has a market capitalization of $1.96 billion, a P/E ratio of -2.53 and a beta of 0.93. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The firm has a fifty day simple moving average of $5.27 and a two-hundred day simple moving average of $5.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company’s quarterly revenue was down 80.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.34) earnings per share. On average, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.43% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.